Cytomegalovirus infection in transplant recipients

Area of Science:

• Transplantation Immunology
• Infectious Diseases
• Virology

Background:

• Cytomegalovirus (CMV) infection is a significant complication following organ and hematopoietic stem cell transplantation.
• CMV infection can arise from transmitted, reactivated, or primary infections, manifesting as latent infection, active infection, viral syndrome, or invasive disease.
• Key risk factors include CMV-seronegative recipients with seropositive donors and the use of lymphocyte-depleting antibodies.

Purpose of the Study:

• To summarize the epidemiology, diagnosis, prevention, and treatment of Cytomegalovirus infection in transplant recipients.
• To highlight the importance of timely intervention to mitigate CMV-related morbidity and mortality.

Main Methods:

• Diagnosis relies on pp65 antigenemia assay and polymerase chain reaction (PCR); histology and bronchoalveolar lavage are used for invasive disease.
• Prevention strategies include prophylaxis with antiviral drugs or preemptive therapy based on early viral replication detection.
• Treatment involves ganciclovir, valganciclovir, or valacyclovir, with intravenous ganciclovir as the gold standard for CMV disease.

Main Results:

• CMV infection typically occurs 30-90 days post-transplant, but earlier in hematopoietic stem cell transplant recipients, especially with graft-versus-host disease.
• Serology is not valuable for diagnosing active CMV disease.
• Prophylaxis duration ranges from 90 to 180 days; treatment lasts 2-3 weeks plus 7 days post-viremia clearance.

Conclusions:

• Effective management of Cytomegalovirus infection post-transplantation requires a combination of risk factor assessment, accurate diagnostics, and appropriate preventive or therapeutic strategies.
• Antiviral therapy, particularly ganciclovir, remains central to controlling CMV disease, emphasizing the need for adherence to treatment durations.